Sanofi’s Enjaymo, once a jewel in its Bioverativ buyout, finally wins its FDA nod for a rare blood disordernews2022-02-04T21:56:31+00:00February 4th, 2022|Fierce Pharma|
Regeneron projects no near-term sales of its blockbuster COVID-19 antibody given FDA action to ground itnews2022-02-04T16:00:29+00:00February 4th, 2022|Fierce Pharma|
The hits keep coming: Biogen’s Aduhelm marketing, approval under fire in new FTC and SEC probesnews2022-02-04T15:58:43+00:00February 4th, 2022|Fierce Pharma|
Bristol busy boosting supply of Breyanzi, Abecma as massive Revlimid patent cliff loomsnews2022-02-04T15:34:09+00:00February 4th, 2022|Fierce Pharma|
Sanofi’s Dupixent rolls on, but US flu shots took backseat to COVID-19 boosters in the fourth quarternews2022-02-04T14:47:49+00:00February 4th, 2022|Fierce Pharma|
UPDATED: Sanofi’s flu shots took a back seat to COVID-19 boosters late last year, and major job cuts still loomnews2022-02-04T14:47:49+00:00February 4th, 2022|Fierce Pharma|
Golic talks to sports figures about treating diabetes with LifeScan OneTouchnews2022-02-04T13:22:02+00:00February 4th, 2022|Fierce Pharma|
Eli Lilly’s Trulicity dethrones Dupixent, taking January’s TV ad spending crownnews2022-02-04T13:17:09+00:00February 4th, 2022|Fierce Pharma|
Fierce Pharma Asia—AstraZeneca China’s fraud investigation; Women promoted at Takeda; Samsung buy of Biogen’s stake in biosimilar JVnews2022-02-04T11:34:32+00:00February 4th, 2022|Fierce Pharma|
Takeda taps a doctor turned patient—and spread-the-word artist—for rare disease awareness campaignnews2022-02-04T09:43:28+00:00February 4th, 2022|Fierce Pharma|
